In last trading session, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) saw 0.42 million shares changing hands with its beta currently measuring 0.21. Company’s recent per share price level of $1.06 trading at -$0.03 or -2.75% at ring of the bell on the day assigns it a market valuation of $8.41M. That closing price of BCLI’s stock is at a discount of -508.49% from its 52-week high price of $6.45 and is indicating a premium of 32.08% from its 52-week low price of $0.72. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.45 million shares which gives us an average trading volume of 1.34 million if we extend that period to 3-months.
For Brainstorm Cell Therapeutics, Inc (BCLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Upright in the red during last session for losing -2.75%, in the last five days BCLI remained trading in the red while hitting it’s week-highest on Monday, 06/23/25 when the stock touched $1.06 price level, adding 15.2% to its value on the day. Brainstorm Cell Therapeutics, Inc’s shares saw a change of -81.97% in year-to-date performance and have moved -13.11% in past 5-day. Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) showed a performance of 0.00% in past 30-days. Number of shares sold short was 0.46 million shares which calculate 0.15 days to cover the short interests.
Brainstorm Cell Therapeutics, Inc (BCLI) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.00% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 30.74% while estimates for its earnings growth in next 5 years are of 29.48%.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Insiders are in possession of 15.98% of company’s total shares while institution are holding 12.89 percent of that, with stock having share float percentage of 15.34%. Investors also watch the number of corporate investors in a company very closely, which is 12.89% institutions for Brainstorm Cell Therapeutics, Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at BCLI for having 7.92 million shares of worth $2.68 million. And as of 2024-06-30, it was holding 11.1179 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.51 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.1212 of outstanding shares, having a total worth of $0.51 million.
On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025 , the former fund manager was holding 31.41 shares of worth $33298.0 or 0.40% of the total outstanding shares. The later fund manager was in possession of 26.73 shares on Mar 31, 2025 , making its stake of worth around $28338.0 in the company or a holder of 0.34% of company’s stock.
